AzTrials
AzTrials

Alveolar Bone LossPhase 4NCT06513039

Evaluation of Erythropoietin on Alveolar Ridge Preservation

A Phase 4 study testing Erythropoietin carried on chitosan carrier and chitosan carrier in people with Alveolar Bone Loss, run by Ain Shams University at 1 site in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

regenerative materials would help in decreasing post-extraction resorption in sites indicated for placement of a conventional bridge or prosthetically driven implant. Erythropoietin (EPO) is a growth factor that promotes angiogenesis and bone regeneration by stimulating osteoblastic differentiation and by inhibiting… Read more about this study

Who is it for?
Ages 18 to 40 yearsHealthy volunteers can take part
Conditions the study is for
Alveolar Bone Loss
What is being tested?
Erythropoietin carried on chitosan carrier and chitosan carrier
Could I receive a placebo?
No, everyone receives an active treatment
How many people
15 participants
Where
1 siteEgypt
Study dates
1 Jan 2024to 1 Jan 2025
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Age range (18-40).
  • Hopeless teeth indicated for extraction such as root fractures, caries, internal root resorption, external root resorption, endodontic failures.
  • Systemically free patients using Cornell Medical Index-Health Questionnaire [36].
  • Patients diagnosed with intact surrounding alveolar bone (socket type I) [37].
  • Maxillary anterior teeth and/or premolars indicated for extraction.
  • Enough zone of keratinized tissue (≥2 mm).

Who cannot join

  • Smokers
  • Occlusal trauma at the site of the graft
  • Pregnancy and lactation
  • Bad compliance with the plaque control instructions following initial therapy.

Trial locations and contacts

1 site in 1 country.

Egypt1 site, 1 recruiting
  • Faculty of Dentistry Ain Shams University

    Cairo, 11361

    Marwa El Kassaby

    Recruiting

Other trials in Egypt

About this study

Official title: Evaluation of Erythropoietin on Alveolar Ridge Preservation: (A Randomized Controlled Clinical Trial With Histomorphometric Assessment)

regenerative materials would help in decreasing post-extraction resorption in sites indicated for placement of a conventional bridge or prosthetically driven implant. Erythropoietin (EPO) is a growth factor that promotes angiogenesis and bone regeneration by stimulating osteoblastic differentiation and by inhibiting osteoclastic resorption. Post-extraction alveolar ridge resorption creates morphological and volumetric changes. These changes can be considered of clinical value that may threaten the placement of a conventional bridge or an implant-supported crown. Atwood et al. [1] in a cephalometric study categorized factors influencing the rate of alveolar ridge resorption into 4 types: anatomic, metabolic, functional, and prosthetic. As stated by Tan et al. [2] in a systematic review of alveolar hard and soft tissue dimensional changes in humans post-extraction, they found that alveolar ridge resorption occurs to a greater extent in a horizontal direction than vertical. Therefore, alveolar ridge preservation (ARP) procedures were introduced in an attempt to prevent hard and soft tissue dimensional changes following extraction.

Read the detailed description

II. Aim of the study:

To assess the efficiency of Erythropoietin in alveolar ridge preservation.

  1. Objectives:

Primary objective:

Dimensional changes of the ridge clinically and radiographically.

Secondary objective:

  1. Postoperative pain.
  2. Postoperative wound healing.
  3. Histomorphometric analysis of the bone regeneration patterns of the extraction sockets.

III. Materials and Methods

  1. Study design and patient selection: It is a randomized controlled clinical trial. Patients will be selected from the outpatient clinic of the Department of Oral Medicine and Periodontology-Ain Shams University and the British University of Egypt. All patients will sign an informed consent about the details of the surgery according to the Ethical Committee Ain Shams University.
  2. Sample size: The sample size was estimated based on assuming confidence level= 95% and study power= 80%. Pandya et al. [29] reported that the Collagen percentage was 2.1%±0.6% in EPO treated sockets while it was 1%±0.6% in non-treated sockets, the average Standard deviation was 0.6%n. The minimum sample size was calculated to be 5 extraction sockets per group. This was increased to 7 sockets to make up for lost to follow-up cases. The total sample size = number of groups × number per group= 3×7= 21 sockets. The sample size was collected by G power 3.0.10.
  3. Eligibility criteria:

Inclusion criteria:

  1. Age range (18-40).
  2. Hopeless teeth indicated for extraction such as root fractures, caries, internal root resorption, external root resorption, endodontic failures.
  3. Systemically free patients using Cornell Medical Index-Health Questionnaire [36].
  4. Patients diagnosed with intact surrounding alveolar bone (socket type I) [37].
  5. Maxillary anterior teeth and/or premolars indicated for extraction.
  6. Enough zone of keratinized tissue (≥2 mm).

Exclusion criteria:

  1. Smokers
  2. Occlusal trauma at the site of the graft
  3. Pregnancy and lactation
  4. Bad compliance with the plaque control instructions following initial therapy.
  5. Interventions:

Pre-surgical phase:

Patients will be initially examined. All patients will receive oral hygiene instructions using roll technique with a soft-bristled toothbrush and interdental floss, and phase I therapy using an ultrasonic device if necessary. At baseline, intraoral periapical radiographs, clinical periodontal measurements including plaque Index [38] , bleeding on probing (BOP) [38], probing depth (PD) [38], and clinical attachment level (CAL) [38] will be recorded at teeth adjacent to the extraction socket area using a UNC periodontal probe [38].

Impressions will be taken using Alginate impression material before the extraction day. Diagnostic casts will be made for the fabrication of a customized stent to standardize the measurements of marginal crestal bone levels at baseline and 4 months post-extraction [39].

Surgical preparation of Extraction socket:

  1. After anesthetizing the surgical field with local anesthesia (4% Articaine , 1: 100 000 epinephrine), An atraumatic extraction procedure will be performed by cutting the periodontal ligaments gently to preserve the buccal plate of bone using periotome and forceps.
  2. The socket will be irrigated with saline and curetted from any granulation tissue following extraction then the buccal and lingual plate of bone will be checked for absence of any fenestration or dehiscence using UNC periodontal probe.
  3. Computer-generated randomization will be used to randomly divide the sockets into three groups. Group I: Extraction sockets filled with CS/ β-GP/gelatin hydrogels loaded EPO until the crestal level. Group II: extraction sockets filled with CS/ β-GP/gelatin hydrogels alone until the crestal level. Group III: Natural healing socket (control group).
  4. In the three groups, the flaps will be sutured with criss-cross horizontal mattress technique with polypropylene 5-0 .

Implant placement Surgery

Patients will return for a follow-up examination at 4 months and implant placement.

  1. After anesthetizing the surgical field with local anesthesia (4% Articaine, 1: 100 000 epinephrine), a papillary sparing will be incised using Bard-Parker scalpel carrying blade number 15C; a crestal flap will be elevated by Molt number 5 mucoperiosteal elevator.
  2. The first drill will be a trephine bur to collect a core bone biopsy; the collected bone will be preserved in a diluted formaldehyde solution to fix the sample to perform the histomorphometry.
  3. Sequential twist drills will be used until the final drill following the implant manufacturer instructions.
  4. In the three groups, the flaps will be sutured with criss-cross horizontal mattress technique suture type using 5-0 polypropylene sutures.

Postoperative care instruction and medication of both surgeries:

  • Patients will be instructed to rinse twice daily with a 0.12% chlorhexidine gluconate solution for 2 weeks, and the sutures will be removed after 2 weeks later.
  • Analgesic and antibiotic drugs were prescribed after the surgical procedure. Ibobrufen (400 mg.) will be prescribed upon patient's need with a maximum dose 2400mg per day for pain relief [40]. Amoxicillin (500 mg.) every 12 hours for 7 days or clindamycin (300 mg.) every 8 hours for 5 days, for patients having a penicillin allergy, three times per day, for infection control [41].
  1. Assessment:
  2. Clinical assessment:
  3. Dimensional changes width changes will be measured using bone caliper at baseline immediately following tooth extraction and 4 months postoperatively [42].
  4. Postoperative Pain level Pain score will be reported by the patient directly through Visual Analogue Scale score (between 0 and 10. 0: no pain, 1: minimal pain, 5: moderate pain, 10: severe pain) VAS will be recorded at day 14 post-extraction [43]. Post-operative pain was assessed indirectly by mean consumption of analgesics for 7 days postoperatively, will be recorded in milligrams[44].
  5. Postoperative wound healing Wound healing will be recorded the 1st and 2 weeks postoperatively through Landry Wound Healing Index (LWHI) [45] which evaluates the extraction site based on tissue color, response to touch, the marginality of the incision line, and extent of the area. The rating is from 1 = very poor to 5 = excellent.
  6. Radiographic assessment:

Dimensional changes will be measured using Cone Beam computed Tomography (CBCT) at baseline immediately following tooth extraction and 4 months postoperatively [42].

  1. Histomorphometric assessment:

Histological and histomorphometric assessment of bone regeneration patterns of core biopsy harvested at the re-entry surgery for implant placement 4 months post extraction using H\&E stains to evaluate bone trabeculae and Modified Masson Trichrome to evaluate bone maturity[46].

Being tested
Erythropoietin carried on chitosan carrier, chitosan carrier
Medical subject headings
Alveolar Bone Loss

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Erythropoietin carried on chitosan carrierDrug

    Patient will have extraction of teeth and placement of Erythropoietin carried on chitosan carrier for six months to enhance bone healing

  • chitosan carrierOther

    inert scaffold agent

Study groups in NCT06513039
Study groupRoleWhat they receive
study groupExperimentalPatient will have extraction of teeth and placement of Erythropoietin carried on chitosan carrier for six months
Receives: Drug: Erythropoietin carried on chitosan carrier
controlNo interventionPatient will have extraction of teeth only and followup
positive controlActive comparatorPatient will have extraction of teeth and placement of chitosan carrier only for six months
Receives: Other: chitosan carrier

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Dimensional changes

    Clinical measurement using bone caliper. Radiographic measurement using CBCT

    Measured: six months

Secondary outcomes (1)
  1. Postoperative Pain level Postoperative wound Healing Patterns of bone regeneration of extraction socket

    Visual analogue scale.

    Measured: six months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Jul 2024
  2. Study start1 Jan 2024
  3. Primary completion1 Jan 2025 (estimated)
  4. Study completion1 Jan 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Three group randomized clinical trial study
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
15 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06513039
Sponsor's protocol ID
1111 phd
Status last verified
Jul 2024
First submitted
14 Jul 2024
Last updated
22 Jul 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: depends on publication requirment at publishing status

Publications

  • Atwood DA. Some clinical factors related to rate of resorption of residual ridges. 1962. J Prosthet Dent. 2001 Aug;86(2):119-25. doi: 10.1067/mpr.2001.117609. No abstract available.

    PubMed 11514795

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Erythropoietin carried on chitosan carrier and chitosan carrier in people with Alveolar Bone Loss, run by Ain Shams University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 22 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Marwa El Kassaby (01001741212, marwaelkassaby@dent.asu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Dimensional changes (time frame: six months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06513039, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in